RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma

Neuroblastoma is a childhood cancer that is often fatal despite intense multimodality therapy. In an effort to identify therapeutic targets for this disease, we performed a comprehensive loss-of-function screen of the protein kinome. Thirty kinases showed significant cellular cytotoxicity when depleted, with loss of the cell cycle checkpoint kinase 1 (CHK1/CHEK1) being the most potent. CHK1 mRNA expression was higher in MYC–Neuroblastoma-related (MYCN)–amplified (P < 0.0001) and high-risk (P = 0.03) tumors. Western blotting revealed that CHK1 was constitutively phosphorylated at the ataxia telangiectasia response kinase target site Ser345 and the autophosphorylation site Ser296 in neuroblastoma cell lines. This pattern was also seen in six of eight high-risk primary tumors but not in control nonneuroblastoma cell lines or in seven of eight low-risk primary tumors. Neuroblastoma cells were sensitive to the two CHK1 inhibitors SB21807 and TCS2312, with median IC50 values of 564 nM and 548 nM, respectively. In contrast, the control lines had high micromolar IC50 values, indicating a strong correlation between CHK1 phosphorylation and CHK1 inhibitor sensitivity (P = 0.0004). Furthermore, cell cycle analysis revealed that CHK1 inhibition in neuroblastoma cells caused apoptosis during S-phase, consistent with its role in replication fork progression. CHK1 inhibitor sensitivity correlated with total MYC(N) protein levels, and inducing MYCN in retinal pigmented epithelial cells resulted in CHK1 phosphorylation, which caused growth inhibition when inhibited. These data show the power of a functional RNAi screen to identify tractable therapeutical targets in neuroblastoma and support CHK1 inhibition strategies in this disease.

[1]  W. Gu,et al.  Non-transcriptional control of DNA replication by c-Myc , 2007, Nature.

[2]  E. Petermann,et al.  Evidence That the ATR/Chk1 Pathway Maintains Normal Replication Fork Progression during Unperturbed S Phase , 2006, Cell cycle.

[3]  John M. Maris,et al.  High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma , 2008, Proceedings of the National Academy of Sciences.

[4]  Yun Dai,et al.  New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network , 2010, Clinical Cancer Research.

[5]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[6]  Gary Box,et al.  The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106 , 2010, Molecular Cancer Therapeutics.

[7]  Jan Koster,et al.  Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. , 2008, Cancer research.

[8]  Jiri Bartek,et al.  Targeting the checkpoint kinases: chemosensitization versus chemoprotection , 2004, Nature Reviews Cancer.

[9]  J. Christensen,et al.  PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts , 2009, Clinical Cancer Research.

[10]  D. Green,et al.  Chk1 Suppresses a Caspase-2 Apoptotic Response to DNA Damage that Bypasses p53, Bcl-2, and Caspase-3 , 2008, Cell.

[11]  D. Stram,et al.  Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. , 1995, European journal of cancer.

[12]  D. Geerts,et al.  Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells , 2009, Proceedings of the National Academy of Sciences.

[13]  J. Rosen,et al.  Chk1 is haploinsufficient for multiple functions critical to tumor suppression. , 2004, Cancer cell.

[14]  J. Maris.  Recent advances in neuroblastoma. , 2010, The New England journal of medicine.

[15]  K. Cimprich,et al.  The ATR pathway: fine-tuning the fork. , 2007, DNA repair.

[16]  A. Look,et al.  CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors , 2009, Molecular Cancer.

[17]  S. Elledge,et al.  Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. , 1997, Science.

[18]  P. Clarke,et al.  DNA-dependent phosphorylation of Chk1 and Claspin in a human cell-free system. , 2005, The Biochemical journal.

[19]  Y. A. Minamishima,et al.  Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. , 2000, Genes & development.

[20]  S. Fesik,et al.  Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. , 2003, Molecular cancer therapeutics.

[21]  O. Fernandez-Capetillo,et al.  ATR signaling can drive cells into senescence in the absence of DNA breaks. , 2008, Genes & development.

[22]  Stephen Green,et al.  AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies , 2008, Molecular Cancer Therapeutics.

[23]  Nazneen Rahman,et al.  Common variations in BARD1 influence susceptibility to high-risk neuroblastoma , 2009, Nature Genetics.

[24]  M. Cole,et al.  High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma , 2010, Clinical Cancer Research.

[25]  Sharon J. Diskin,et al.  A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene , 2008, Molecular Cancer Research.

[26]  Pumin Zhang,et al.  DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Meredith C Henderson,et al.  Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer , 2009, Journal of Translational Medicine.

[28]  B. Ducommun,et al.  Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy. , 2009, Cancer research.

[29]  R. Beijersbergen,et al.  Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. , 2009, Cancer cell.

[30]  C. Britten,et al.  G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer , 2008, British Journal of Cancer.

[31]  Enhong Chen,et al.  Structure-Based Design of (5-Arylamino-2H-pyrazol-3-yl)-biphenyl-2‘,4‘-diols as Novel and Potent Human CHK1 Inhibitors , 2007 .

[32]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[33]  T. Helleday,et al.  Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control , 2008, Proceedings of the National Academy of Sciences.

[34]  J. Jackson,et al.  An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. , 2000, Cancer research.